Tyra Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Tyra Biosciences, Inc. on May 29, 2025. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol TYRA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: Three Class I directors were elected for a three-year term expiring at the 2028 Annual Meeting.
- Todd Harris, Ph.D.: 33,878,966 votes For; 6,434,333 votes Withheld; 5,043,580 Broker Non-Votes.
- Adele M. Gulfo: 40,310,667 votes For; 2,632 votes Withheld; 5,043,580 Broker Non-Votes.
- S. Michael Rothenberg, M.D., Ph.D.: 33,731,963 votes For; 6,581,336 votes Withheld; 5,043,580 Broker Non-Votes.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Votes: 45,356,001 For; 235 Against; 643 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific term expiration dates for the newly elected Class I directors.
- Review the full proxy statement for detailed biographies of the elected directors and the rationale for the auditor ratification.